A Phase 1, Dose-escalation, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1353 in Healthy Volunteers
Latest Information Update: 29 Mar 2023
At a glance
- Drugs SYNB 1353 (Primary) ; Methionine
- Indications Homocystinuria
- Focus Adverse reactions
- Sponsors Synlogic
- 20 Mar 2023 According to an Synlogic media release, data from this study were presented at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting.
- 16 Mar 2023 Status changed from recruiting to completed.
- 30 Nov 2022 According to a Synlogic media release, all subjects completing the 28-day analysis cleared SYNB1353 in feces, full results of the study will be presented at a future medical meeting.